{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:59:07Z","timestamp":1783763947088,"version":"3.55.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Fibroblast growth factor 23 (FGF-23) has been associated with increased cardiovascular risk and poor survival in dialysis patients. It is well established that FGF-23 synthesis is directly induced by positive phosphate (P) balance. On the other hand, P-lowering treatments such as nutritional P restriction, P binders and dialysis are capable of reducing FGF-23 levels. However, there are many uncertainties regarding the possibility of adopting FGF-23 to guide the clinical decision-making process in the context of chronic kidney disease\u2013mineral bone disorder (CKD-MBD). Furthermore, the best assay to adopt for measurement of FGF-23 levels (namely the intact vs the C-terminal one) remains to be determined, especially in conditions capable of altering the synthesis as well as the cleavage of the intact and biologically active molecule, as occurs in the presence of CKD and its complications. This Editorial discusses the main insights provided by the post hoc analysis of the NOPHOS trial, with particular attention given to evidence-based peculiarities of the intact and the C-terminal assays available for measuring FGF-23 levels, especially in patients receiving additive P-lowering therapy in the presence of inflammation, anemia and iron deficiency.<\/jats:p>","DOI":"10.1093\/ckj\/sfad144","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T04:33:08Z","timestamp":1687840388000},"page":"1543-1549","source":"Crossref","is-referenced-by-count":2,"title":["The open system of FGF-23 at the crossroad between additional P-lowering therapy, anemia and inflammation: how to deal with the intact and the C-terminal assays?"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-1332","authenticated-orcid":false,"given":"Lorenza","family":"Magagnoli","sequence":"first","affiliation":[{"name":"University of Milan, Department of Health Sciences , Milano , Italy"},{"name":"ASST Santi Paolo e Carlo, Renal Division , Milano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-6252","authenticated-orcid":false,"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"University of Milan, Department of Health Sciences , Milano , Italy"},{"name":"ASST Santi Paolo e Carlo, Renal Division , Milano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galassi","sequence":"additional","affiliation":[{"name":"University of Milan, Department of Health Sciences , Milano , Italy"},{"name":"ASST Santi Paolo e Carlo, Renal Division , Milano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"2023092902524236300_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) foreword","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"2023092902524236300_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ki.2009.246","article-title":"A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease","volume":"76","author":"Isakova","year":"2009","journal-title":"Kidney Int"},{"key":"2023092902524236300_bib3","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"2023092902524236300_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/MAJ.0b013e3181815498","article-title":"Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients","volume":"337","author":"Hsu","year":"2009","journal-title":"Am J Med Sci"},{"key":"2023092902524236300_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","article-title":"Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community","volume":"205","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"key":"2023092902524236300_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1570161115666170310092202","article-title":"Klotho-FGF23, cardiovascular disease, and vascular calcification: black or white?","volume":"16","author":"Cianciolo","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"2023092902524236300_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf","year":"2012","journal-title":"Kidney Int"},{"key":"2023092902524236300_bib8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902524236300_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"2023092902524236300_bib11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/nep.14081","article-title":"Impact of etelcalcetide on fibroblast growth factor-23 and calciprotein particles in patients with secondary hyperparathyroidism undergoing haemodialysis","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Nephrology"},{"key":"2023092902524236300_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ckj\/sfz034","article-title":"Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis","volume":"13","author":"Wolf","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023092902524236300_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-14-112","article-title":"Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study","volume":"14","author":"Kim","year":"2013","journal-title":"BMC Nephrol"},{"key":"2023092902524236300_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.03270314","article-title":"Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism","volume":"10","author":"Sprague","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902524236300_bib15","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1681\/ASN.2015020117","article-title":"Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD","volume":"26","author":"Isakova","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2023092902524236300_bib16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"2023092902524236300_bib17","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","article-title":"Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients","volume":"26","author":"Gonzalez-Parra","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/ndt\/gfr388","article-title":"Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study)","volume":"27","author":"Shigematsu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5414\/CN107257","article-title":"Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study","volume":"78","author":"Toida","year":"2012","journal-title":"Clin Nephrol"},{"key":"2023092902524236300_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2023092902524236300_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients","volume":"80","author":"Soriano","year":"2013","journal-title":"Clin Nephrol"},{"key":"2023092902524236300_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000351811","article-title":"Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease","volume":"123","author":"Spatz","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"2023092902524236300_bib23","doi-asserted-by":"crossref","first-page":"e0201537","DOI":"10.1371\/journal.pone.0201537","article-title":"Phosphate control in reducing FGF23 levels in hemodialysis patients","volume":"13","author":"Rodelo-Haad","year":"2018","journal-title":"PLoS One"},{"key":"2023092902524236300_bib24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/ndt\/gfy127","article-title":"Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease\u2013mineral bone disorder parameters in dialysis patients","volume":"34","author":"Ketteler","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ndt\/gfy061","article-title":"The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia","volume":"34","author":"Block","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib26","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1681\/ASN.2020101398","article-title":"A randomized trial of tenapanor and phosphate binders as a dual-mechanism treatment for hyperphosphatemia in patients on maintenance dialysis (AMPLIFY)","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2023092902524236300_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"key":"2023092902524236300_bib28","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease\u2013associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"2023092902524236300_bib29","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1007\/s10157-016-1362-9","article-title":"Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients","volume":"21","author":"Chang","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"2023092902524236300_bib30","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/ndt\/gfs418","article-title":"COSMOS: the dialysis scenario of CKD\u2013MBD in Europe","volume":"28","author":"Fern\u00e1ndez-Mart\u00edn","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1681\/ASN.2018101058","article-title":"Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: the COMBINE trial","volume":"30","author":"Ix","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2023092902524236300_bib32","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000362424","article-title":"Effect of niacin on FGF23 concentration in chronic kidney disease","volume":"39","author":"Rao","year":"2014","journal-title":"Am J Nephrol"},{"key":"2023092902524236300_bib33","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","article-title":"Nicotinamide suppresses hyperphosphatemia in hemodialysis patients","volume":"65","author":"Takahashi","year":"2004","journal-title":"Kidney Int"},{"key":"2023092902524236300_bib34","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","author":"Cheng","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023092902524236300_bib35","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/ndt\/gfx249","article-title":"Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study","volume":"32","author":"Lenglet","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad040","article-title":"Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients","author":"Egli-Spichtig","year":"2023","journal-title":"Clin Kidney J"},{"key":"2023092902524236300_bib37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ekir.2020.12.012","article-title":"Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis\u2014a randomized clinical trial","volume":"6","author":"Ketteler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2023092902524236300_bib38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ndt\/gfac206","article-title":"Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial","volume":"38","author":"Ketteler","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2023092902524236300_bib39","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1128\/MCB.02249-06","article-title":"Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members","volume":"27","author":"Goetz","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2023092902524236300_bib40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1073\/pnas.0902006107","article-title":"Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation","volume":"107","author":"Goetz","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023092902524236300_bib41","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ki.2008.643","article-title":"Latest findings in phosphate homeostasis","volume":"75","author":"Pri\u00e9","year":"2009","journal-title":"Kidney Int"},{"key":"2023092902524236300_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbadis.2008.09.016","article-title":"GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity","volume":"1792","author":"Chefetz","year":"2009","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2023092902524236300_bib43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/jbmr.516","article-title":"Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease","volume":"27","author":"Stubbs","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2023092902524236300_bib44","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1210\/jc.2009-1603","article-title":"Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active","volume":"95","author":"Shimada","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2023092902524236300_bib45","doi-asserted-by":"crossref","first-page":"e4875","DOI":"10.1210\/clinem\/dgaa665","article-title":"Intact and C-terminal FGF23 assays\u2014do kidney function, inflammation, and low iron influence relationships with outcomes?","volume":"105","author":"Sharma","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023092902524236300_bib46","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.3324\/haematol.2016.150987","article-title":"Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease","volume":"102","author":"Courbebaisse","year":"2017","journal-title":"Haematologica"},{"key":"2023092902524236300_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00223-022-00987-9","article-title":"The measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations","volume":"112","author":"Heijboer","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"2023092902524236300_bib48","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2023092902524236300_bib49","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2023092902524236300_bib50","doi-asserted-by":"crossref","first-page":"F1369","DOI":"10.1152\/ajprenal.00281.2016","article-title":"Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice","volume":"311","author":"Hanudel","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023092902524236300_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"2023092902524236300_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","article-title":"Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease","volume":"94","author":"Durlacher-Betzer","year":"2018","journal-title":"Kidney Int"},{"key":"2023092902524236300_bib53","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s11010-022-04422-3","article-title":"Interconnections of fibroblast growth factor 23 and klotho with erythropoietin and hypoxia-inducible factor","volume":"477","author":"Afsar","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"2023092902524236300_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.kint.2021.04.030","article-title":"Novel roles of HIF-phis in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23","volume":"100","author":"Ikeda","year":"2021","journal-title":"Kidney Int"},{"key":"2023092902524236300_bib55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40266-019-00696-3","article-title":"Management of secondary hyperparathyroidism in chronic kidney disease: a focus on the elderly","volume":"36","author":"Galassi","year":"2019","journal-title":"Drugs Aging"},{"key":"2023092902524236300_bib56","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/j.ajkd.2020.10.008","article-title":"Design and rationale of HiLo: a pragmatic, randomized trial of phosphate management for patients receiving maintenance hemodialysis","volume":"77","author":"Edmonston","year":"2021","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfad144\/50820415\/sfad144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1543\/51788654\/sfad144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/10\/1543\/51788654\/sfad144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:56:12Z","timestamp":1695956172000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/10\/1543\/7209178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,6,27]]},"published-print":{"date-parts":[[2023,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfad144","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,6,27]]}}}